Feasibility studies
We can help you lower your production biomolecule percentage, using our PlanTech technology.
Production outsourcing
We’ll provide an annual subscription of the proteins we developed for you.
Facility set-up
We install the facility, give you proper training and provide support with certification.
Licensing
And when you’re ready, we’ll handle licensing so that you can use our platform at your site.
Tiamat is on a mission to fuel the next biotechnology revolution. We are reinventing biomolecule production with our plant-based platform.
Our Executive Team
France-Emmanuelle is an experienced biochemist with a background in the pharmaceutical industry. She is deeply committed to making changes with a large-scale impact in the industry and it is her mission to create a shift towards sustainability and circularity.
Prathima is a seasoned executive with over 20 years of experience in the biotech industry with expertise in the development and manufacturing of biotech products leading to IND/BLA filings. Prathima has consistently driven critical initiatives and innovative strategies and has orchestrated operations to achieve sustainable growth and profitability.
Montana is a dynamic leader with a proven track record in program and people management and over 10 years of industry experience in the biotech and healthcare industries. She drives impactful change by focusing on process improvement, streamlining operations, and increasing efficiency, all while maintaining exceptional employee engagement, 26% higher than industry standards.
Kelli comes to us with 15 years of business experience from corporate finance, investor relations, marketing, and strategy. Most recently she was the Chief of Staff for an early-stage start-up helping them complete a $21M oversubscribed Series A fundraise. Prior to that she was an Associate Director of Finance for Optum working on pricing and financial planning and analysis.
Edric has 30 years of experience in healthcare as a VC venture partner, an SME in PE, an operating partner with C-Suite roles at portfolio companies along with experience running business units, key global functions, and leading key initiatives at McKinsey & Company. His focus is growth strategy and turnarounds and how to create integrated, downstream solutions from value propositions to capital planning to business development and infrastructure builds.
Plants, the new bioreactors
Our plants are sustainable by design. They have an inherently low contamination risk and their rapid growth allows for fast product development iterations.
Our Team
Chip brings over 20 years biotech industry experience (AgBiome, Bayer Crop, Synthon, Biolex) with extensive background and experience in molecular biology/genetic engineering, vectoring, designing & assembling constructs for plant transformations including N. benthamiana, and transient expression in plants.
Christian has 7 years biotech industry experience at Biogen with extensive background and experience in Analytical Development, Quality Control, and Tech Transfer for clinical and commercial biotech Drug Substance and Drug Products. He also brings industry experience in Assay Qualification, Assay Validation (ICH), cGMP, SOPs, and Regulatory experience.
Our Board
France-Emmanuelle is an experienced biochemist with a background in the pharmaceutical industry. She is deeply committed to making changes with a large-scale impact in the industry and it is her mission to create a shift towards sustainability and circularity.
Ryan is a serial entrepreneur & investor active in the novel food & biotech fields. Currently, he is CEO of Wild Earth (Healthy and Sustainable Plantbased Pet Food), co-founder at Sustainable Food Ventures & Tiamat's board member and advisor. Ryan's mission is to positively impact the lives of billions of people and animals through applied biotechnology.